FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:960-961 April 6, 1995 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Gram, L. F.

To the Editor: In his review of fluoxetine (Nov. 17 issue),¹ Dr. Gram failed to mention two studies of inpatients with major depression who had improvement with fluoxetine comparable to that with desipramine² or imipramine³ and that an analysis of results from controlled studies of more than 1500 patients with mild, moderate, or severe depression revealed no differences in rates of response or remission between patients receiving fluoxetine and those receiving tricyclic antidepressant drugs.⁴ With regard to drug tolerance, a meta-analysis of 42 randomized, controlled studies examined rates of drug discontinuation due to lack of efficacy or side effects in . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Goldstein, B. J., Goodnick, P. J (1998). Selective serotonin reuptake inhibitors in the treatment of affective disorders--III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 12: 55-S87 [Abstract]